Principles of cancer biotherapy / edited by Robert K. Oldham, Robert O. Dillman.
"At the time of the first edition of Principles of Cancer Biotherapy in 1987, this book represented the first comprehensive textbook on biological therapy. In 1991, when the second edition was published, there was still some doubt on the part of many oncologists and cancer researchers as to the...
Saved in:
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Format: | Ebook |
| Language: | English |
| Published: |
Dordrecht :
Springer,
2009.
|
| Edition: | 5th ed. |
| Subjects: | |
| Online Access: | Springer eBooks |
MARC
| LEADER | 00000nzm a22000004i 4500 | ||
|---|---|---|---|
| 005 | 20231002160116.0 | ||
| 007 | cr n | ||
| 008 | 090527s2009 ne a ob 001 0 eng | ||
| 010 | |z 2009929387 | ||
| 011 | |a BIB MATCHES WORLDCAT | ||
| 011 | |a EDS identifier machine added through SSID matching | ||
| 011 | |a GMD replaced with 3XX, non-RDA. | ||
| 020 | |a 9048122899 |q Internet | ||
| 020 | |a 9789048122899 |q Internet | ||
| 020 | |z 9048122775 (hbk. (alk. paper)) | ||
| 020 | |z 9789048122776 (hbk. (alk. paper)) | ||
| 035 | |a (EDS)EDS596113 | ||
| 035 | |a (OCoLC)489218893 | ||
| 040 | |a NLM |c NLM |d UKM |d ZCH |d COU |d DEBBG |d BTCTA |d YDXCP |d OHX |d TPH |d DLC |d WaSeSS |d ATU | ||
| 042 | |a pcc | ||
| 050 | 4 | |a Online | |
| 245 | 0 | 0 | |a Principles of cancer biotherapy / |c edited by Robert K. Oldham, Robert O. Dillman. |
| 250 | |a 5th ed. | ||
| 264 | 1 | |a Dordrecht : |b Springer, |c 2009. | |
| 300 | |a 1 electronic document. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 500 | |a Description based on print version record. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | 0 | |t Cancer biotherapy: general principles / |r Robert K. Oldham -- |t The pathogenesis of cancer metastasis: relevance to therapy / |r Sun-Jin Kim, Cheryl Hunt Baker, Yasuhiko Kitadai, Toru Nakamura, Toshio Kuwai, Takamitsu Sasaki et al. -- |t Developmental therapeutics and the design of clinical trials / |r Robert K. Oldham -- |t Recombinant proteins and genomics in cancer therapy / |r Kapil Mehta, Bulent Ozpolat, Kishorchandra Gohil, Bharat B. Aggarwal -- |t Current concepts in immunology / |r Robert K. Oldham -- |t Therapeutic approaches to cancer-associated immune suppression / |r Robert K. Oldham -- |t Cancer vaccines / |r Kenneth A. Foon, Malek M. Safa -- |t Cytokines / |r Walter M. Lewko, Robert K. Oldham -- |t Interferons: therapy for cancer / |r David Goldstein, Robert Jones, Richard V. Smalley, Ernest C. Borden -- |t Monoclonal antibody therapy / |r Robert O. Dillman -- |t Immunotoxins / |r Arthur E. Frankel, Jung-Hee Woo, David M. Neville -- |t Drug Immunoconjugates / |r Malek Safa, Kenneth A. Foon, Robert K. Oldham -- |t Targeted radionuclide therapy of cancer / |r John M. Pagel, Otto C. Boerman, Hazel B. Breitz, Ruby F. Meredith -- |t Stem cell/bone marrow transplantation as biotherapy / |r Robert K. Oldham -- |t Cellular immunotherapy (CI), where have we been and where are we going? / |r John R. Yannelli -- |t Growth and differentiation factors as cancer therapeutics / |r Kapil Mehta, Robert K. Oldham, Bulent Ozpolat -- |t Granulocyte colony-stimulating factor: biology and clinical potential / |r MaryAnn Foote, George Morstyn -- |t Granulocyte-macrophage colony-stimulating factor / |r Maryann Foote, George Morstyn -- |t Cancer gene therapy / |r Donald J. Buchsbaum, C. Ryan Miller, Lacey R. Mcnally, Sergey A. Kaliberov -- |t Regulatory process for approval of biologicals for cancer therapy / |r Antonio J. Grillo-López -- |t Cancer biotherapy: 2009 disease-related activity / |r Robert K. Oldham, Robert O. Dillman -- |t Biological therapy of melanoma / |r Robert K. Oldham -- |t Biological therapy of genitourinary cancer / |r Robert K. Oldham -- |t Biological therapy of colon cancer / |r Robert O. Dillman -- |t Biological therapy of breast cancer / |r Robert O. Dillman -- |t Biological therapy of lung cancer / |r Robert O. Dillman -- |t Biological therapy of B and T cell lymphoproliferative disorders / |r Robert O. Dillman -- |t Biological therapy of multiple myeloma / |r Robert K. Oldham -- |t Biological therapy of squamous cell cancers of the head and neck / |r Robert O. Dillman -- |t Biological therapy of glioblastoma / |r Robert O. Dillman -- |t Speculations for 2009 and beyond / |r Robert K. Oldham. |
| 520 | |a "At the time of the first edition of Principles of Cancer Biotherapy in 1987, this book represented the first comprehensive textbook on biological therapy. In 1991, when the second edition was published, there was still some doubt on the part of many oncologists and cancer researchers as to the therapeutic value of these new approaches. By 2003 and the fourth edition, it was generally agreed that biopharmaceuticals were producing major opportunities for new cancer therapies. Cancer biotherapy has now truly matured into the fourth modality of cancer treatment. This fifth revised edition describes the tremendous progress that has been made in recent years using biologicals in cancer treatment.This book summarizes an evolving science and a rapidly changing medical practice in biotherapy. In this new millennium, it is now possible to envision a much more diversified system of cancer research and treatment that will afford greater opportunities for a patient’s personalized cancer treatment. This was first envisioned in the 1987 initial edition of this textbook and is now a “new” and popular approach to cancer treatment. Some forms of cancer biotherapy use the strategy of tumor stabilization and control through continued biological therapy, akin to the use of insulin in the treatment of diabetes.This textbook illustrates new methods of thinking and new strategies for control of cancer. It is always difficult to move from past dogma to future opportunity, but this fifth edition of Principles of Cancer Biotherapy illustrates why it is so important to the patients for researchers and clinicians to explore and quickly apply these new opportunities in cancer biotherapy."--Publisher's website. | ||
| 538 | |a Mode of access: World Wide Web. | ||
| 588 | |a Automated GMD conversion. | ||
| 650 | 0 | |a Biological products |x Therapeutic use. |9 335968 | |
| 650 | 0 | |a Biological response modifiers. |9 314562 | |
| 650 | 0 | |a Cancer |x Immunotherapy. |9 326546 | |
| 650 | 2 | |a Antineoplastic Agents |x therapeutic use. |9 362731 | |
| 650 | 2 | |a Immunotherapy. |9 362569 | |
| 700 | 1 | |a Dillman, Robert O. |9 821812 | |
| 700 | 1 | |a Oldham, Robert K. |9 307887 | |
| 710 | 2 | |a SpringerLink ebooks - Biomedical and Life Sciences (2009) | |
| 856 | 4 | 0 | |u https://ezproxy.aut.ac.nz/login?url=https://link.springer.com/10.1007/978-90-481-2289-9 |z Springer eBooks |x TEMPORARY ERM URL |
| 907 | |a .b12843313 |b 12-03-21 |c 28-10-15 | ||
| 942 | |c EB | ||
| 998 | |a none |b 23-06-17 |c m |d z |e - |f eng |g ne |h 0 | ||
| 999 | |c 1247145 |d 1247145 | ||